Ikić D, Singer Z, Beck M, Soos E, Sips D, Jusić D
J Cancer Res Clin Oncol. 1981;101(3):303-8. doi: 10.1007/BF00410115.
Human leukocyte interferon (HLI) was used in a randomized study of patients with precancerous states on the uterine cervix. The daily dose of HLI was 10(6) units and its was applied by the contraceptive pessary technique. In patients how had had only viral alterations on the cervix the treatment lasted 14 days (Singer et al. 1979) and in those with changed cytologic findings 21 days. The cytologic findings of the interferon treated patients showed no progression of the pathologic process during the ensuing 2 years. In the control group, however, they showed the aggravation of the process and the patients were directed to surgical therapy. The control of cytologic findings has been continued and in now performed at 3 month intervals.
人白细胞干扰素(HLI)被用于一项针对子宫颈癌前状态患者的随机研究。HLI的日剂量为10⁶单位,采用避孕子宫托技术给药。对于仅宫颈有病毒改变的患者,治疗持续14天(辛格等人,1979年),对于细胞学检查结果有变化的患者,治疗持续21天。接受干扰素治疗的患者的细胞学检查结果显示,在随后的2年中病理过程没有进展。然而,在对照组中,病理过程出现了加重,患者被转至手术治疗。细胞学检查结果的监测一直在持续,现在每隔3个月进行一次。